


Name: Retatrutide cat#: EX-A7826E

Chemical Structure:



Sequence:	Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH ₂		
-----------	--	--	--

Molecular Weight	4731.3477	Storage	1 year 2- 4°C powder
Formula	C ₂₂₁ H ₃₄₂ N ₄₆ O ₆₈		2 years -20°C powder
CAS No.	2381089-83-2	Synonyms	6 months -80°C in solvent
			Away from light
			LY3437943; LY-3437943

Solubility (25°C) *	In vitro	DMSO	N/A
		Ethanol	N/A
		Water	Soluble
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass Volume Concentration	1 mg	5 mg	10 mg
1 mM	0.2114 mL	1.0568 mL	2.1136 mL
5 mM	0.0423 mL	0.2114 mL	0.4227 mL
10 mM	---	---	---

H₂O :

*The above data is based on the product molecular weight 4731.35.

Biological Activities:

Description	Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR, and GLP-1R with EC ₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively.
--------------------	---

References	[1]. Urva, Shweta et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." Lancet (London, England) vol. 400,10366 (2022): 1869-1881. [2]. Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
-------------------	--